Abstract: The present invention provides 3D edible scaffolds and methods for the production thereof. The invention further discloses edible inks for use in tissue engineering (TE) applications, such as growing and/or supporting 3D engineered tissues, particularly 3D nutritious engineered edible tissues intended for cultured meat applications.

Abstract: An aspect of some embodiments of the invention relates to methods of manufacturing a 3D printed implant, comprising printing a mold of a scaffold, generating said scaffold from said mold, seeding cells on said scaffold, where said generating said scaffold comprises generating parts of said scaffold with different levels of stiffness.

Abstract: The present invention provides pharmaceutical compositions comprising membrane vesicles, including extracellular vesicles including those referred to as exosomes, loaded with an exogenous Phosphatase and tensin homolog (PTEN) inhibitor. Methods of treating neurological diseases, disorders or conditions using the extracellular vesicles are provided. Isolated extracellular vesicles loaded with an exogenous Phosphatase and tensin homolog (PTEN) inhibitor are provided as well.

Abstract: The present invention provides methods and systems for enhanced production and/or secretion of extracellular vesicles (EVs) from muscle cells utilizing various dynamic mechanical loading profiles thereon, cultured on three-dimensional (3D) scaffolds. The scaffolds may comprise a plurality of layers, wherein each layer comprises a plurality of elastic microfibers, and wherein the microfibers are aligned in parallel to a longitudinal axis and to each other. The elastic 3D scaffold may be configured to undergo dynamic mechanical loading profiles and support an expansion of a population of muscle cells cultured thereon into a 3D multi-layer structure of muscle cells, wherein said 3D multi-layer structure is configured to produce and/or secret extracellular vesicles into a medium.

Abstract: The present invention provides pharmaceutical compositions comprising membrane vesicles, including extracellular vesicles including those referred to as exosomes, loaded with an exogenous Phosphatase and tensin homolog (PTEN) inhibitor. Methods of treating neurological diseases, disorders or conditions using the extracellular vesicles are provided. Isolated extracellular vesicles loaded with an exogenous Phosphatase and tensin homolog (PTEN) inhibitor are provided as well.

Abstract: A kappa-carrageenan (Kcar) granular hydrogel devoid of a cell-toxic crosslinking agent is provided as a scaffold for maintaining and implanting cellular structures such as lumens. The lumens may be defined by cells or surrounded by cells and may have the dimensions of a blood vessel.

Abstract: An aspect of the invention relates to methods and implants comprising acoustic-sensitive material and at least one additional component within said acoustic-sensitive material. In some embodiments, the at least one additional component is one or more of at least one releasable drug within said acoustic-sensitive material and/or a plurality of cells within said acoustic-sensitive material. In some embodiments, the implant comprises a dedicated form, which is provided inside the body of the patient.

Abstract: Microfluidic devices and methods thereof; the devices including: SNDA components; each SNDA component comprising: a primary channel; secondary channels; and nano-wells that are each open to the primary channel and are each connected via vents to the secondary channel; the vents are configured to enable passage of gas solely from the nano-wells to the secondary channel, such that when a fluid is introduced into the primary channel it fills the nano-wells, and the originally accommodated gas is evacuated via the vents and the secondary channel/s; a common inlet port, configured to enable a simultaneous introduction of the fluid into all the primary channels of the different SNDA components; individual inlet ports, configured to enable individual introduction of fluid, each into a different primary channel of a different SNDA component; and at least one outlet port, configured to enable evacuation of the gas out of all the secondary channels.

Abstract: A device comprising: plurality of Stationary Nanoliter Droplet Array (SNDA) components; each SNDA component comprising: at least one primary channel; at least one secondary channel; and a plurality of nano-wells that are each open to the primary channel and are each connected by one or more vents to the secondary channel; the vents are configured to enable passage of air solely from the nano-wells to the secondary channel, such that when a liquid is introduced into the primary channel it fills the nano-wells, and the originally accommodated air is evacuated via the vents and the secondary channel/s; an inlet port and a distribution channel configured to enable a simultaneous introduction of the liquid into all primary channels; and an outlet port and an evacuation channel configured to enable a simultaneous evacuation of the air out of all the secondary channels.

Abstract: Methods for making an implant scaffold, comprising providing a 3D template generated according to an image of a lesion site, contacting the 3D template with a solution comprising a polymeric precursor, and evaporating the solution, thereby obtaining an implant scaffold, are provided. Further, implant scaffolds, comprising a water-soluble template in the form of a 3D geometrical array and a polymeric material are provided.

Abstract: The present invention provides an implant which includes: (a) an autologous engineered tissue; and (b) a vasculature, wherein the engineered tissue is a porous scaffold embedded with endothelial cell, a fibroblast, a myoblast, a mesenchymal cell, an adipocyte, or any combination thereof, wherein the vasculature feeds the cells. Further, the invention provides a method for treating a subject afflicted with a large soft tissue defect by implanting the implant of the invention.

Abstract: A three-dimensional fibrin engineered tissue construct is provided selected from: (i) a fibrin gel matrix comprising a combination of tissue-specific cells and at least one type of vascular cells; and (ii) a hybrid scaffold of fibrin gel and a polymeric synthetic scaffold comprising at least one type of vascular cells or a combination of tissue-specific cells and at least one type of vascular cells.

Abstract: The present invention provides methods and systems for enhanced production and/or secretion of extracellular vesicles from at least one three-dimensional porous scaffold having a population of stem cells cultured thereon, utilizing various shear stress conditions on a variety of stem cells.

Abstract: The present invention provides pharmaceutical compositions comprising membrane vesicles, including extracellular vesicles including those referred to as exosomes, loaded with an exogenous Phosphatase and tensin homolog (PTEN) inhibitor. Methods of treating neurological diseases, disorders or conditions using the extracellular vesicles are provided. Isolated extracellular vesicles loaded with an exogenous Phosphatase and tensin homolog (PTEN) inhibitor are provided as well.

Abstract: A flow bioreactor device for monitoring cellular dynamics may include a housing having one or a plurality of conduits to place one or a plurality of tissue samples inside each of said one or a plurality of conduits, wherein each of said one or a plurality of conduits has an inlet for introducing a flow of a liquid in a direction of flow through that conduit, wherein said one or a plurality of conduits are fluidically linked to an outlet for discharging the liquid, and wherein at least a portion of the housing is transparent so as to provide a line of sight for viewing or for an optical device along an elongated axis of any of said one or a plurality of conduits, the line of sight being substantially parallel to the direction of flow through that conduit.

Abstract: The present invention is directed to, inter alia, a scaffold-cell construct including a biocompatible polymer (e.g., poly-l-lactic acid (PLLA) and polylactic glycolic acid (PLGA)) and recombinant cells having increased GLUT4 levels and/or activity. The invention is further directed to methods for reducing glucose levels in a subject in need thereof. Also provided are methods of producing the scaffold-cell construct of the invention.

Abstract: The invention is directed to a method for producing an edible composition, comprising incubating a three-dimensional porous scaffold and a plurality of cell types comprising: myoblasts or progenitor cells thereof, at least one type of extracellular (ECM)-secreting cell and endothelial cells or progenitor cells thereof, and inducing myoblasts differentiation into myotubes.

Abstract: A microfluidic device may include a microstructure formed in a substrate, the microstructure including a primary channel with a first end and a second end, and a plurality of chambers that open to the primary channel. At least two openings coupled to the first end of the primary channel may be used to load at least two fluid streams into the device through the first end of the primary channel to flow along the primary channel from the first end to the second end into the plurality of chambers, each chamber of the plurality of chambers having a volume less than 100 nanoliters and connected by a vent to a secondary channel in the micro structure, a width of the vent configured to enable a gas to escape from the chamber to the secondary channel while inhibiting the flow of said at least first and second fluid streams into the secondary channel.

Abstract: The present invention provides a composition based on poly-l-lactic acid (PLLA) acid polylactic-co-glycolic-acid (PLGA) scaffold on which neuronal tissue can ex-vivo grow. Further, more the invention provides a method for making cellular vasculature networks and a method for treating a neuronal injury in a subject, by implanting the current composition.

Abstract: A method of treating a spinal cord injury in a subject in need thereof is disclosed. The method comprises implanting a scaffold into the spinal cord of a subject, wherein the scaffold is seeded with oral mucosa stem cells (OMSC) and/or cells that have been ex vivo differentiated from said OMSCs, thereby treating the spinal cord injury.